- Source : Press Release
- Date : 2020-03-25
- Companies : Evonik Industries AG
Evonik Wins Special Champion Status in All Six Categories at the 2020 Life Science Leader CMO Leadership Awards
Evonik, one of the world's largest and most specialized CMOs for APIs, HPAPIs and advanced intermediates, today announced it was one of only a few companies to have received a special Champion award across all six eligible categories at the 2020 Life Science Leader CMO Leadership Awards.
“To have been named by our customers as a Champion CMO across all categories is a tremendous honour,” said Dr. Andreas Meudt, Vice President of Exclusive Synthesis from Evonik's Health Care business line. “We are grateful for the trust our customers place in us every day to manufacture their life-saving APIs and intermediates. We are committed to providing them with the Western-based manufacturing network, advanced technologies and technical expertise they need to reduce quality and regulatory risk and maximize supply security.”
“Our Health Care business line is a key growth segment of Evonik,” said Johann-Caspar Gammelin, Chairman of the Board of Management of Evonik Nutrition & Care. “These awards further validate our position as a preferred development partner and solutions provider to pharmaceutical and biotech companies.”
Life Science Leader magazine teamed up with Industry Standard Research (ISR) to assess more than 125 CMOs across more than 20 performance metrics as part of its 2020 Contract Manufacturing Quality Benchmarking survey of global pharmaceutical and biotechnology companies. For the third consecutive year, participating companies voted for Evonik to earn awards for its Capabilities, Compatibility, Expertise, Quality, Reliability and Service. Because Evonik was rated as a top performer compared to its CMO peers, each category award was upgraded to a special Champion status. Evonik was one of only a select few CMOs to receive a Champion award in all six of its eligible categories.
Evonik is one of the world's three top CMOs for APIs and intermediates, with the largest manufacturing capacity for high potency APIs (HPAPIs). To address the specific needs of large or complex projects, it has established a broad portfolio of advanced technologies which can be combined to support multi-step API synthesis. These technologies include continuous processes, fermentation, PEGs and mPEGs, catalysts, biocatalysts, cryogenic chemistry and polymer APIs. To meet growing customer demand for its CMO services, Evonik will continue to expand its technology portfolio and make other continuous improvement measures under its “Best-in-Class” initiative at U.S. and European sites.
For many specialized therapy areas, Evonik can now manufacture the customer's API, select and supply the right functional excipient, develop the parenteral or oral formulation, and manufacture the finished drug product. In addition to this integrated portfolio of services, many customers are also attracted by Evonik's stability and proud record for sustainability.
Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €13.1 billion and an operating profit (adjusted EBITDA) of €2.15 billion in 2019. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 32,000 employees work together for a common purpose: We want to improve life, day by day.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,200 employees, and generated sales of around €4.6 billion in 2019.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.